Premium
Anticarbohydrate Antibody Repertoires in Patients Transplanted with Fetal Pig Islets Revealed by Glycan Arrays
Author(s) -
Blixt O.,
KumagaiBraesch M.,
Tibell A.,
Groth C. G.,
Holgersson J.
Publication year - 2009
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2008.02471.x
Subject(s) - transplantation , antibody , medicine , islet , immunology , isoantibodies , titer , heterophile , antigen , glycan , biology , diabetes mellitus , endocrinology , microbiology and biotechnology , glycoprotein
Ten patients with type I diabetes were transplanted with porcine fetal islet‐like cell clusters (ICC) between 1990 and 1993. A significant rise in the anti‐α‐Gal antibody titers was seen posttransplant, but also non‐α‐Gal‐specific antibodies were detected in some patients. We have reanalyzed the carbohydrate specificity of antibodies in the sera from seven of these patients taken before transplantation, 1, 6 and 12 months posttransplantation using a glycan array with 200 structurally defined glycans. The main findings were: (i) prepig ICC transplantation patients had antibodies reactive with terminal α‐GalNAc (e.g. the Forssman antigen, but not the blood group A determinant in blood group A patients), α‐Gal (except blood group B determinants in B individuals), β3‐linked Gal especially Galβ1,3GlcNAc even if terminally sulfated or sialylated, β‐GlcNAc except if β1,3‐linked and oligomannosyl compounds; (ii) the titers of all carbohydrate‐specific antibodies detected before transplantation rose after transplantation; (iii) the kinetics of the antibody responses differed between patients; (iv) in some patients antibodies reacting with Galα1,3Le x and several structures terminated with Neu5Gc appeared after transplantation. In conclusion, anti‐α‐Gal antibodies are the predominant anticarbohydrate antibodies detected after porcine ICC transplantation, with some patients also developing Neu5Gc‐specific antibodies. Their clinical significance needs to be established.